
Opinion|Videos|November 4, 2023
Treatment Approaches for R/R Follicular Lymphoma in the 3L and Beyond
An expert discussion surrounding the evolving treatment landscape for relapsed or refractory follicular lymphoma in the third-line setting and beyond.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5





!["I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/11e93c561a9ff98f731b152d7f48e6f792831864-1000x1000.jpg?w=350&fit=crop&auto=format)



















































